Drug intelligence / Profile preview

Fenoget

Development stage: Unknown
Lead developer: Getz Bros. & Company
Modality: Small Molecules
Administration: Oral

Overview

Fenoget is a marketed generic formulation of fenofibrate, a fibric acid derivative developed and manufactured by Getz Pharma. It is indicated as an adjunctive therapy to diet for the treatment of adult patients with primary hypercholesterolemia, mixed dyslipidemia, and hypertriglyceridemia. Fenoget works as an agonist of the peroxisome proliferator-activated receptor alpha (PPAR-alpha), which activates lipoprotein lipase and reduces the production of apolipoprotein C-III, thereby enhancing the clearance of triglyceride-rich particles and improving the overall lipid profile by lowering low-density lipoprotein cholesterol (LDL-C), total cholesterol, and triglycerides, while increasing high-density lipoprotein cholesterol (HDL-C).

Brand names: Fenoget
Other names: fenofibrate

Targets

PPARA (Peroxisome proliferator-activated receptor alpha)

Beyond the preview

Go deeper on Fenoget.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fenoget.